Renal Oxygenation, Oxygen Consumption and Hemodynamic Kinetics in Type 2 DIabetes: an Ertugliflozin Study.

Group 1: T2DM patients Inclusion criteria * Provision of signed and dated, written informed consent prior to any study specific procedures. * Caucasian\*; female or male aged ≥18 years and \<80 years. Females must be post-menopausal (defined as no menses \>1 year and follicle stimulating hormone (FSH) \>31 U/L)\*. * Type 2 diabetes mellitus since at least 3 years with HbA1c ≥ 6.5% (≥57mmol/mol) and \<10% (\<94mmol/mol) * An appropriate stable dose of metformin and/or sulfonylurea as glucose-lowering therapy for the last 12 weeks * Maximum tolerated antihypertensive dose of an ARB for at least 6 weeks prior to randomization. * eGFR 60-90 ml/min/1.73m² * BMI 25-35 kg/m² \* In order to increase homogeneity Exclusion criteria * Involvement in the planning and/or conduction of another study * Participation in another clinical study with an investigational product during the last 3 months * Diagnosis of type 1 diabetes mellitus * CKD defined as eGFR\<60 ml/min/1.73m² or albuminuria (defined as an UACR \> 2.5 mg/mol). * Cardiovascular disease event in the last 6 months prior to enrollment as assessed by the investigator, including: myocardial infarction, cardiac surgery or revascularization (CABG/PTCA), unstable angina, heart failure, transient ischemic attack (TIA) or significant cerebrovascular disease, unstable or previously undiagnosed arrhythmia. * Current/chronic use of the following medication: insulin, thiazolidinediones, GLP-1 receptor agonists, DPP-4 inhibitors, SGLT-2…